Spine proton ablative radiotherapy achieved 74% two-year local control in selected patients
Spine proton ablative radiotherapy achieved 74% local control at one and two years, with no radiation myelopathy in a reirradiation-enriched cohort.
Latest
Medial retropharyngeal nodes were involved in 2.95% of non-endemic nasopharyngeal cancers
Medial retropharyngeal nodes were involved in 2.95% of German cases, but no recurrence occurred among patients whose elective volume omitted the region.
Particle therapy costing studies show major methodological heterogeneity
Only 12 eligible studies were found, with inconsistent methods and assumptions that limited meaningful comparison of particle therapy costs.
Fraction 15 was optimal for one-time offline replanning in head and neck proton therapy
A single offline replan at fraction 15 captured most achievable dosimetric benefit in simulated head and neck proton therapy.
MRI-guided prostate SBRT reduced low-dose exposure to sexual-function structures
MRI-guided SBRT with 2-mm margins reduced low- and intermediate-dose exposure of neurovascular bundles and pudendal arteries versus CT-guided treatment.
DEGRO supports ultrahypofractionation for localized prostate cancer but flags higher late urinary toxicity
DEGRO supports ultrahypofractionation for low- to intermediate-risk prostate cancer, with comparable control but increased late genitourinary toxicity in selected patients.
Intratumoral polyvinyl chloride was associated with radioresistance in hepatocellular carcinoma
PVC was detected in 37 of 72 HCC tumors and was associated with poorer response and progression-free survival after SBRT, immunotherapy, and bevacizumab.
Durvalumab improved 2-year progression-free survival after chemoradiotherapy in real-world stage III NSCLC
Consolidation durvalumab after concurrent chemoradiotherapy halved the adjusted risk of progression or death at two years in real-world stage III NSCLC.
Surface-contacted 3D bolus plus MLC reduced proton PBS lateral penumbra
Surface-contacted 3D boluses generally narrowed lateral penumbra and reduced surrounding dose versus a nozzle-mounted range shifter in proton PBS.
Five-fraction prostate and pelvic nodal SBRT showed low late toxicity
After prostate and pelvic nodal SBRT, no grade ≥3 late GU or GI toxicity occurred among 101 patients with high-risk disease.
Multidisciplinary radiopharmaceutical dosimetry changed management in one-third of selected patients
In 19 high-risk patients receiving 177Lu-PSMA-617, post-cycle 1 dosimetry changed management in 32%, prompting five activity reductions and one delay.
Cardiac toxicity occurred in 8% after central and ultracentral lung SBRT
Symptomatic grade ≥2 cardiac toxicity occurred in 8% after central or ultracentral lung SBRT, typically developing more than one year after treatment.
Lower microvascular health predicted acute radiotherapy toxicity across three cancer cohorts
Lower pretreatment microvascular health was associated with more acute toxicity overall, while disease-specific performance was strongest in breast cancer.
Lung SBRT studies use inconsistent definitions of local control
Nearly one-third of lung SBRT studies counted failures beyond the treated tumor as local events, limiting comparison of reported control rates.
FLASH attenuated inflammatory and pro-fibrotic lung transcription after irradiation
In mice, FLASH reduced acute chemokine and later macrophage-associated transcription versus conventional irradiation, without significantly reducing collagen deposition.